314 related articles for article (PubMed ID: 9328363)
21. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
22. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
[TBL] [Abstract][Full Text] [Related]
24. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
Eschbach JW; Varma A; Stivelman JC
Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
[TBL] [Abstract][Full Text] [Related]
25. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
26. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients.
Teruel JL; Lasuncion MA; Rivera M; Aguilera A; Ortega H; Tato A; Marcen R; Ortuño J
Am J Kidney Dis; 1997 Apr; 29(4):569-75. PubMed ID: 9100047
[TBL] [Abstract][Full Text] [Related]
27. Androgens for the treatment of anemia in peritoneal dialysis patients.
Navarro JF; Mora-Fernández C; Rivero A; Macía M; Gallego E; Chahin J; Méndez ML; García J
Adv Perit Dial; 1998; 14():232-5. PubMed ID: 10649731
[TBL] [Abstract][Full Text] [Related]
28. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
Abu-Alfa AK; Cruz D; Perazella MA; Mahnensmith RL; Simon D; Bia MJ
Am J Kidney Dis; 2000 Jun; 35(6):1076-82. PubMed ID: 10845820
[TBL] [Abstract][Full Text] [Related]
29. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
30. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
31. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
32. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
[TBL] [Abstract][Full Text] [Related]
34. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
35. Effects of androgen therapy on prostatic markers in hemodialyzed patients.
Teruel JL; Aguilera A; Avila C; Ortuño J
Scand J Urol Nephrol; 1996 Apr; 30(2):129-31. PubMed ID: 8738058
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
[TBL] [Abstract][Full Text] [Related]
37. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
[TBL] [Abstract][Full Text] [Related]
38. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
39. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
Johansen KL; Mulligan K; Schambelan M
JAMA; 1999 Apr; 281(14):1275-81. PubMed ID: 10208142
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
Lezaic V; Djukanovic L; Pavlovic-Kentera V
Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
